Abelacimab

DB16682InvestigationalProtein Based Therapies

Abelacimab is under investigation in clinical trial NCT04755283 (Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation).

Mechanism: Pharmacologically active on Coagulation factor XI
Curator reviewed
Code names: MAA-868

Resolves to

Compound

UNIIKX1N4TV7UYCAS2098724-83-3

Targets

P03951F11

What you can answer from here — as of April 14, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

8Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Abelacimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account